NICE shoots down AstraZeneca's Faslodex, citing dearth of survival data
admin 1st September 2017 Uncategorised 0It was a good week for AstraZeneca’s Faslodex—until Friday. England’s National Institute of Health and Care Excellence (NICE) released draft guidance recommending against use of the elderly breast cancer med as an option for delaying growth of estrogen-receptor positive breast cancer that has spread to other parts of the body in patients who haven’t yet been treated with hormonal therapy.
More: NICE shoots down AstraZeneca's Faslodex, citing dearth of survival data
Source: fierce